18, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced strategic financing from Blue Owl Capital (Blue Owl) and Canada Pension Plan Investment Board (CPP Investments), through a wholly owned subsidiary (CPPIB Credit) of CPPIB Credit Investments Inc., bringing in capital of up to $1.25 billion.

2024年1月18日（环球通讯社）--BridgeBio Pharma，Inc.（纳斯达克：BBIO）（BridgeBio或该公司），一家专注于遗传疾病和癌症的商业阶段生物制药公司，今天宣布通过CPPIB Credit Investments Inc.的全资子公司（CPPIB Credit），从Blue Owl Capital（Blue Owl）和加拿大养老金计划投资委员会（CPP Investments）获得战略融资，带来高达12.5亿美元的资本。

With these transactions, BridgeBio obtains financing from experienced healthcare investors who share the Company’s confidence in the anticipated launch of acoramidis as the potential backbone of therapy for transthyretin amyloid cardiomyopathy (ATTR-CM). “We are excited to be working with a distinguished group of life sciences investors who are aligned with our view of acoramidis’ blockbuster market opportunity,” said Brian Stephenson, Ph.D., CFA, Chief Financial Officer of BridgeBio.

通过这些交易，BridgeBio从经验丰富的医疗保健投资者那里获得了资金，他们对acoramidis的预期推出充满信心，acoramidis是甲状腺素转运蛋白淀粉样心肌病（ATTR-CM）治疗的潜在支柱。BridgeBio首席财务官布莱恩·斯蒂芬森博士（BrianStephenson）表示：“我们很高兴能与一群杰出的生命科学投资者合作，他们与我们对acoramidis的巨大市场机会的看法一致。”。

“Our newly strengthened balance sheet will enable us to serve ATTR-CM patients with a well-resourced launch of acoramidis, as well as patients with genetic diseases more broadly with multiple Phase 3 readouts for blockbuster indications anticipated over the next few years. Our increasing patient impact should allow us to diversify drivers of top line revenue in the near term and enable reinvestment into R&D paired with opportunistic business development.”

“我们新近增强的资产负债表将使我们能够通过推出资源充足的 acoramidis 来为 ATTR-CM 患者提供服务，并通过针对未来几年预计的重磅适应症的多个 3 期读数来为更广泛的遗传病患者提供服务。 我们不断增加的患者影响应该使我们能够在短期内实现营收驱动因素的多元化，并能够对研发进行再投资，并结合机会性业务发展。”

The overall collaboration includes the following key features: A royalty agreement with Blue Owl and CPPIB Credit: $500 million cash payment upon FDA approval of acoramidis to help support the Company’s commercial launch in exchange for future royalties of 5% of worldwide net sales of acoramidis, both of which are subject to various conditions. This consists of $300 million from Blue Owl and $200 million from CPPIB Credit Total royalty payments are capped at 1.9 times the invested capital, and the royalty agreement includes investment features (such as change of control provisions that apply prior to FDA approval) intended to provide broad strategic flexibility for BridgeBio going forward A refinancing with Blue Owl of BridgeBio’s existing senior credit facility: $450 million of committed capital funded at close to refinance BridgeBio’s existing senior credit facility, extending maturity from 2026 to 2029 and providing the Company with considerable operational flexibility An additional tranche of up to $300 million, funded at the Company and Blue Owl’s mutual consent to support strategic corporate development activities

整体合作包括以下主要特点： 与 Blue Owl 和 CPPIB Credit 签订的特许权使用费协议： FDA 批准 acoramidis 后，将支付 5 亿美元现金，以帮助支持该公司的商业推出，以换取 acoramidis 全球净销售额 5% 的未来特许权使用费，两者均受各种条件限制。其中包括来自 Blue Owl 的 3 亿美元和来自 CPPIB Credit 的 2 亿美元 特许权使用费总额上限为投资资本的 1.9 倍，特许权使用费协议包括投资特征（例如 FDA 批准之前适用的控制条款变更），旨在为 BridgeBio 未来提供广泛的战略灵活性 与 Blue Owl 对 BridgeBio 现有高级信贷额度进行再融资： 4.5 亿美元的承诺资本为 BridgeBio 现有的高级信贷安排提供了接近再融资，将期限从 2026 年延长至 2029 年，并为公司提供了相当大的运营灵活性 经公司和 Blue Owl 双方同意追加最多 3 亿美元的资金，用于支持战略性企业发展活动

“Blue Owl is well-positioned to provide bespoke and scaled financing solutions to the most consequential companies in the life sciences sector,” said Sandip Agarwala, Managing Director at Blue Owl Capital. “Acoramidis has demonstrated an impressive and differentiated clinical profile, and we believe it will be an important advancement in the treatment of ATTR-CM. Further, BridgeBio’s promising pipeline of late-stage targeted rare disease therapies address critical unmet needs in these underserved populations. We are pleased to support BridgeBio in its mission of bringing breakthrough medicines to patients.”

Blue Owl Capital 董事总经理 Sandip Agarwala 表示：“Blue Owl 处于有利地位，可以为生命科学领域最有影响力的公司提供定制和规模化的融资解决方案。” “Acoramidis 已展现出令人印象深刻且差异化的临床特征，我们相信这将是 ATTR-CM 治疗的重要进步。此外，BridgeBio 前景广阔的晚期靶向罕见疾病疗法可解决这些服务不足的人群中未得到满足的关键需求。我们很高兴支持 BridgeBio 履行为患者带来突破性药物的使命。”

“This investment in BridgeBio represents an opportunity to provide structured capital solutions to an innovative company in the healthcare space and leverage CPP Investments’ deep capabilities in life sciences,” said David Colla, Managing Director and Head of Capital Solutions, CPP Investments. “Investments in leading therapies also help to diversify our capital allocations to income streams that are typically uncorrelated to the broader capital markets.”

CPP Investments 董事总经理兼资本解决方案主管 David Colla 表示：“对 BridgeBio 的投资代表了一个机会，可以为医疗保健领域的创新公司提供结构化资本解决方案，并利用 CPP Investments 在生命科学领域的深厚能力。” “对领先疗法的投资还有助于将我们的资本配置多元化到通常与更广泛的资本市场不相关的​​收入流。”

Morgan Stanley & Co. LLC acted as sole structuring agent on the transactions. Latham & Watkins served as legal advisor to BridgeBio and Cooley LLP advised Blue Owl.

摩根士丹利有限责任公司 (Morgan Stanley & Co. LLC) 担任本次交易的独家结构代理。Latham & Watkins 担任 BridgeBio 的法律顾问，Cooley LLP 担任 Blue Owl 的法律顾问。